<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370536</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 40-5004</org_study_id>
    <nct_id>NCT03370536</nct_id>
  </id_info>
  <brief_title>ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization</brief_title>
  <official_title>Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized, un-blinded, observational trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multicenter observational study will examine the ability of ECGi mapping to&#xD;
&#xD;
        1. Effect of Ibutilide on the number and size of the driver domains&#xD;
&#xD;
        2. Effect of ablation of Ibutilide-organized driver domains&#xD;
&#xD;
        3. Effect of PV isolation on driver domains&#xD;
&#xD;
      The researchers hypothesize that this approach will lead to successful arrhythmia control .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1 patient enrolled (consented) but screen failed. Study stopped as unable to enroll.&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">July 18, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who no Longer Has Recurrent At/AF</measure>
    <time_frame>at 12 months</time_frame>
    <description>Freedom from recurrent At/AF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of drivers identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Size of drivers ablated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Driver Regions</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Percent change of driver regions after ibutilide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF Termination Rate</measure>
    <time_frame>post ablation inducibility of AF after 5 minutes of burst pacing</time_frame>
    <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>within 24 hours after the procedure is completed the time is calculated</time_frame>
    <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AF and planned to undergo first catheter procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioInsight ECGI Mapping System</intervention_name>
    <description>The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>ECGi mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>Empiric ablation (CFAE or linear ablation) is not permitted</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>Biosense Thermocool SF</other_name>
    <other_name>Biosense Smart Touch SF (STSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)</description>
    <arm_group_label>Patients with AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  ° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III&#xD;
             antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained&#xD;
             &gt; 7 days. Episodes of AF which are terminated by electrical or pharmacologic&#xD;
             cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified&#xD;
             as persistent AF episodes.&#xD;
&#xD;
               -  Planned to undergo first catheter ablation procedure ( prior atrial flutter&#xD;
                  typical is allowed)&#xD;
&#xD;
          -  Ability to understand the requirements of the study and sign the informed consent&#xD;
             form.&#xD;
&#xD;
          -  Willingness to adhere to study restrictions and comply with all post-procedural&#xD;
             follow-up requirements&#xD;
&#xD;
          -  Projected lifespan greater than 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They have baseline prolonged QT or renal failure precluding safe used of ibutilide&#xD;
&#xD;
          -  Rheumatic heart disease,&#xD;
&#xD;
          -  Current intra-cardiac thrombus,&#xD;
&#xD;
          -  History of MI or CABG within 6 weeks;&#xD;
&#xD;
          -  Class IV HF,&#xD;
&#xD;
          -  Unable to sign consent&#xD;
&#xD;
          -  Projected lifespan of &lt; 1 year&#xD;
&#xD;
          -  Women known to be pregnant or to have positive beta-HCG.&#xD;
&#xD;
          -  Participation in another study that would interfere with this study.&#xD;
&#xD;
          -  Unstable Angina&#xD;
&#xD;
          -  Recent cerebral ischemic events&#xD;
&#xD;
          -  Contraindication to anticoagulation&#xD;
&#xD;
          -  Prior history of polymorphic ventricular tachycardia or torsades de pointes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Koruth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>AFIB</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibutilide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03370536/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With AF</title>
          <description>Patients with AF and planned to undergo first catheter procedure&#xD;
CardioInsight ECGI Mapping System: The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.&#xD;
AF ablation: Empiric ablation (CFAE or linear ablation) is not permitted&#xD;
Ibutilide: Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Atrial Fibrillation (AF)</title>
          <description>Patients with AF and planned to undergo first catheter procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who no Longer Has Recurrent At/AF</title>
        <description>Freedom from recurrent At/AF</description>
        <time_frame>at 12 months</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who no Longer Has Recurrent At/AF</title>
          <description>Freedom from recurrent At/AF</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Drivers</title>
        <description>Number of drivers identified</description>
        <time_frame>Baseline</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drivers</title>
          <description>Number of drivers identified</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Drivers</title>
        <description>Size of drivers ablated</description>
        <time_frame>Baseline</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Drivers</title>
          <description>Size of drivers ablated</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Driver Regions</title>
        <description>Percent change of driver regions after ibutilide</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Driver Regions</title>
          <description>Percent change of driver regions after ibutilide</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AF Termination Rate</title>
        <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
        <time_frame>post ablation inducibility of AF after 5 minutes of burst pacing</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>AF Termination Rate</title>
          <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
        <time_frame>within 24 hours after the procedure is completed the time is calculated</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Participant screen failed</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients With Atrial Fibrillation (AF)</title>
          <description>Patients with AF and planned to undergo first catheter procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vivek Reddy</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 241-7114</phone>
      <email>vivek.reddy@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

